Citizens Sticks With Market Outperform for Summit Therapeutics as Ivonesimab Program Expands
Citizens has reaffirmed its Market Outperform rating and a $40.00 price target on Summit Therapeutics plc (NASDAQ:SMMT). The stock trades at $16.09 with a market capitalization of $12.41 billion, even as InvestingPro flags potential overvaluation versus Fair Value. Summit is extending ivonesimab beyond non-small cell lung cancer into late-stage tri…